<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="manner" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">4. Discussion</segment>
<segment id="2" parent="1003" relname="span">Understanding mechanisms of viral strategy</segment>
<segment id="3" parent="2" relname="purpose">to evade from host antiviral responses is critical for elucidation of the pathogenesis of CSFV infection .</segment>
<segment id="4" parent="1004" relname="joint">Type I IFNs represent one of the first lines of defense of the innate immune system</segment>
<segment id="5" parent="1004" relname="joint">and are produced rapidly upon recognition of viral factors by PRRs .</segment>
<segment id="6" parent="1006" relname="span">CSFV is known to interfere with the generation of type I IFNs</segment>
<segment id="7" parent="6" relname="means">by inducing proteasomal degradation of IRF3 .</segment>
<segment id="8" parent="1007" relname="contrast">Type III IFNs play a critical role in antiviral innate immunity in mucosal epithelial cells .</segment>
<segment id="9" parent="1009" relname="span">However , little information is available</segment>
<segment id="10" parent="9" relname="elaboration">as to whether and how CSFV modulates type III IFN response .</segment>
<segment id="11" parent="1012" relname="attribution">The present study demonstrates</segment>
<segment id="12" parent="1012" relname="span">that the Npro protein of CSFV inhibited IRF1-mediated type III IFNs production</segment>
<segment id="13" parent="12" relname="means">by down-regulation of IRF1 expression and blockage of its nuclear translocation .</segment>
<segment id="14" parent="1014" relname="span">The Npro-deleted mutant showed similar growth kinetics to its parental strain ,</segment>
<segment id="15" parent="1016" relname="attribution">indicating</segment>
<segment id="16" parent="1016" relname="span">that CSFV Npro does not alter the replication in cell culture ,</segment>
<segment id="17" parent="16" relname="elaboration">which is consistent with the previous study .</segment>
<segment id="18" parent="1018" relname="span">Some viruses have evolved</segment>
<segment id="19" parent="18" relname="purpose">to encode viral antagonists for evasion of type III IFNs responses .</segment>
<segment id="20" parent="1008" relname="joint">Reid et al showed the induction of type III IFNs in pDCs upon BVDV infection ,</segment>
<segment id="21" parent="1008" relname="joint">and type III IFNs contributed to suppression of cellular immune response during BVDV infection .</segment>
<segment id="22" parent="23" relname="attribution">Cai et al shows</segment>
<segment id="23" parent="1023" relname="span">that CSFV induced the expression of type III IFNs in PK-15 cells ,</segment>
<segment id="24" parent="1024" relname="span">but with a limited level of increase ,</segment>
<segment id="25" parent="1025" relname="span">suggesting that CSFV might have a strategy</segment>
<segment id="26" parent="25" relname="purpose">to suppress expression of type III IFNs .</segment>
<segment id="27" parent="1027" relname="span">We also found limited up-regulation of type III IFNs transcription upon wtCSFV infection in IPEC-J2 cells ,</segment>
<segment id="28" parent="1028" relname="joint">though the transcription level peaked at 24 hpi</segment>
<segment id="29" parent="1029" relname="span">and decreased thereafter ,</segment>
<segment id="30" parent="1031" relname="span">which is different from the results</segment>
<segment id="31" parent="30" relname="elaboration">shown by Cai et al</segment>
<segment id="32" parent="1032" relname="span">that the mRNA level of IFN-λ1 and IFN-λ3</segment>
<segment id="33" parent="32" relname="elaboration">induced by wtCSFV peaked at 36 and 48 hpi , respectively .</segment>
<segment id="34" parent="1035" relname="attribution">We speculate</segment>
<segment id="35" parent="1035" relname="span">that the difference might be due to different cell types</segment>
<segment id="36" parent="35" relname="elaboration">used .</segment>
<segment id="37" parent="38" relname="circumstance">Because CSFV causes enteric pathologies ,</segment>
<segment id="38" parent="1037" relname="span">a cell line from the intestines could be a good choice .</segment>
<segment id="39" parent="1039" relname="span">The IPEC-J2 cell line was from non-transformed cells</segment>
<segment id="40" parent="1040" relname="joint">collected from the jejunum of a neonatal piglet</segment>
<segment id="41" parent="1040" relname="joint">and suitable for infection studies for enteropathogens .</segment>
<segment id="42" parent="1008" relname="joint">IPEC-J2 exhibited robust expression of type III IFNs with a relatively lower type I IFNs response .</segment>
<segment id="43" parent="1043" relname="preparation">Thus , the IPEC-J2 cell line was chosen in this study .</segment>
<segment id="44" parent="1044" relname="preparation">Cell lines or primary cultures from other intestinal areas or from adult pigs could be approached for further investigation of the interactions between CSFV and type III IFNs .</segment>
<segment id="45" parent="46" relname="attribution">We found</segment>
<segment id="46" parent="1045" relname="span">that the ∆Npro mutant induced significantly higher transcription of IFNs in IPEC-J2 cells from 24 to 48 hpi than its parental strain ,</segment>
<segment id="47" parent="48" relname="attribution">suggesting</segment>
<segment id="48" parent="1047" relname="span">that the Npro protein might be antagonistic to expression of type III IFNs .</segment>
<segment id="49" parent="1049" relname="span">Because CSFV Npro has been found to subvert the type I IFN response ,</segment>
<segment id="50" parent="51" relname="attribution">we speculated</segment>
<segment id="51" parent="1050" relname="span">if Npro might have similar effect on type III IFNs .</segment>
<segment id="52" parent="1053" relname="attribution">We showed</segment>
<segment id="53" parent="1053" relname="joint">that wtCSFV strongly inhibited expression of poly(I : C)-induced type III IFNs in IPEC-J2 cells</segment>
<segment id="54" parent="1053" relname="joint">and Npro deletion abolished such an inhibitory effect .</segment>
<segment id="55" parent="56" relname="attribution">We further showed</segment>
<segment id="56" parent="1055" relname="span">that Npro over-expression led to a marked reduction of mRNA transcripts of type III IFNs .</segment>
<segment id="57" parent="1046" relname="joint">Either infection with wtCSFV or over-expression of Npro also resulted in significant reduction of the IFN-λ3 promoter activity of poly(I : C)-treated IPEC-J2 cells .</segment>
<segment id="58" parent="1059" relname="attribution">These results demonstrate</segment>
<segment id="59" parent="1059" relname="span">that CSFV employs its Npro</segment>
<segment id="60" parent="1060" relname="span">to inhibit type III IFNs expression</segment>
<segment id="61" parent="1061" relname="span">probably by targeting the regulatory elements</segment>
<segment id="62" parent="61" relname="elaboration">involved in transcription of IFN-λs .</segment>
<segment id="63" parent="1046" relname="joint">Activation of type III IFNs , as the case with type I IFNs ,</segment>
<segment id="64" parent="1046" relname="joint">requires IRF3 , IRF7 and NF-κB .</segment>
<segment id="65" parent="1065" relname="preparation">However , expression of type III IFNs does not need all components of the enhanceosome .</segment>
<segment id="66" parent="1065" relname="joint">IRF1 is a predominant antiviral molecule against many viruses .</segment>
<segment id="67" parent="68" relname="concession">It is the first identified member of the IRF family ,</segment>
<segment id="68" parent="1067" relname="span">but it does not induce production of type I IFNs .</segment>
<segment id="69" parent="70" relname="attribution">Odendall et al has shown</segment>
<segment id="70" parent="1069" relname="span">that IRF1 regulates peroxisome-mediated IFN-λ1 expression .</segment>
<segment id="71" parent="1071" relname="span">Epithelial cells have preference</segment>
<segment id="72" parent="71" relname="elaboration">of producing IFN-λs over IFN-α/β upon viral infection .</segment>
<segment id="73" parent="1065" relname="joint">This may be due to relatively higher expression of peroxisomes in epithelial cells .</segment>
<segment id="74" parent="1075" relname="span">Peroxisomal MAVS is known to induce type III IFNs ,</segment>
<segment id="75" parent="74" relname="manner">as opposed to induction of type I IFNs via mitochondrial MAVS .</segment>
<segment id="76" parent="1076" relname="span">To better understand the regulation of type III IFNs by IRF1 ,</segment>
<segment id="77" parent="76" relname="elaboration">we attempted to regulate levels of IRF1 expression by overexpression or RNA interference in IPEC-J2 cells .</segment>
<segment id="78" parent="1065" relname="joint">Overexpression of IRF1 led to a significant increase of transcription of all IFN-λs and IFN-λ3 promoter activity ,</segment>
<segment id="79" parent="1079" relname="concession">while gene silencing showed opposite effects ,</segment>
<segment id="80" parent="81" relname="attribution">indicating</segment>
<segment id="81" parent="1079" relname="span">that IRF1 positively regulates expression of type III IFNs .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1005" relname="background"/>
<group id="1003" type="span" parent="1004" relname="background"/>
<group id="1004" type="multinuc" parent="1002" relname="span"/>
<group id="1005" type="multinuc" parent="1001" relname="span"/>
<group id="1006" type="span" parent="1005" relname="joint"/>
<group id="1007" type="multinuc" parent="1005" relname="joint"/>
<group id="1008" type="multinuc" parent="1007" relname="contrast"/>
<group id="1009" type="span" parent="1008" relname="joint"/>
<group id="1011" type="span" parent="1008" relname="joint"/>
<group id="1012" type="span" parent="1011" relname="span"/>
<group id="1014" type="span" parent="1008" relname="joint"/>
<group id="1015" type="span" parent="14" relname="elaboration"/>
<group id="1016" type="span" parent="1015" relname="span"/>
<group id="1018" type="span" parent="1008" relname="joint"/>
<group id="1022" type="span" parent="1008" relname="joint"/>
<group id="1023" type="span" parent="1024" relname="concession"/>
<group id="1024" type="span" parent="1022" relname="span"/>
<group id="1025" type="span" parent="24" relname="elaboration"/>
<group id="1027" type="span" parent="1008" relname="joint"/>
<group id="1028" type="multinuc" parent="27" relname="concession"/>
<group id="1029" type="span" parent="1028" relname="joint"/>
<group id="1030" type="multinuc" parent="29" relname="elaboration"/>
<group id="1031" type="span" parent="1030" relname="same_unit"/>
<group id="1032" type="span" parent="1030" relname="same_unit"/>
<group id="1034" type="span" parent="1008" relname="joint"/>
<group id="1035" type="span" parent="1034" relname="span"/>
<group id="1037" type="span" parent="1008" relname="joint"/>
<group id="1039" type="span" parent="1008" relname="joint"/>
<group id="1040" type="multinuc" parent="39" relname="elaboration"/>
<group id="1042" type="span" parent="1008" relname="joint"/>
<group id="1043" type="span" parent="1042" relname="span"/>
<group id="1044" type="span" parent="1043" relname="span"/>
<group id="1045" type="span" parent="1046" relname="preparation"/>
<group id="1046" type="multinuc" parent="1044" relname="span"/>
<group id="1047" type="span" parent="1046" relname="joint"/>
<group id="1049" type="span" parent="1046" relname="joint"/>
<group id="1050" type="span" parent="49" relname="manner"/>
<group id="1052" type="span" parent="1046" relname="joint"/>
<group id="1053" type="multinuc" parent="1052" relname="span"/>
<group id="1055" type="span" parent="1046" relname="joint"/>
<group id="1058" type="span" parent="1046" relname="joint"/>
<group id="1059" type="span" parent="1058" relname="span"/>
<group id="1060" type="span" parent="59" relname="purpose"/>
<group id="1061" type="span" parent="60" relname="means"/>
<group id="1064" type="span" parent="1046" relname="joint"/>
<group id="1065" type="multinuc" parent="1064" relname="span"/>
<group id="1067" type="span" parent="1065" relname="joint"/>
<group id="1069" type="span" parent="1065" relname="joint"/>
<group id="1071" type="span" parent="1065" relname="joint"/>
<group id="1074" type="span" parent="1065" relname="joint"/>
<group id="1075" type="span" parent="1074" relname="span"/>
<group id="1076" type="span" parent="1075" relname="purpose"/>
<group id="1078" type="span" parent="1065" relname="joint"/>
<group id="1079" type="span" parent="1078" relname="span"/>
	</body>
</rst>
